Ayala Pharmaceuticals, Inc.

$ Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224014822 Filed on April 16, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023

Balance Sheet

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.212M	$5.212M
YoY Change	-79.32%	-79.32%
Cash & Equivalents	$4.900M	$4.882M
Short-Term Investments	$330.0K	$330.0K
Other Short-Term Assets	$172.0K	$2.316M
YoY Change	-68.78%	320.33%
Inventory
Prepaid Expenses	$2.646M
Receivables
Other Receivables
Total Short-Term Assets	$7.528M	$7.528M
YoY Change	-70.78%	-70.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$540.0K	$642.0K
YoY Change	1321.05%	1184.0%
Goodwill	$4.500M
YoY Change
Intangibles	$3.898M
YoY Change	3443.64%
Long-Term Investments
YoY Change
Other Assets	$11.00K	$11.00K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$9.051M	$9.051M
YoY Change	5192.98%	5192.98%
TOTAL ASSETS
Total Short-Term Assets	$7.528M	$7.528M
Total Long-Term Assets	$9.051M	$9.051M
Total Assets	$16.58M	$16.58M
YoY Change	-36.06%	-36.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.076M	$6.076M
YoY Change	27518.18%	27518.18%
Accrued Expenses	$6.506M	$6.506M
YoY Change	202.6%	543.52%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$25.00M	$25.02M
YoY Change	985.54%	986.32%
LONG-TERM LIABILITIES
Long-Term Debt	$8.141M	$8.141M
YoY Change
Other Long-Term Liabilities	$7.837M	$7.837M
YoY Change
Total Long-Term Liabilities	$15.98M	$15.98M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.00M	$25.02M
Total Long-Term Liabilities	$15.98M	$15.98M
Total Liabilities	$40.98M	$41.00M
YoY Change	1679.33%	1680.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$197.2M
YoY Change	-55.48%
Common Stock	$12.00K
YoY Change	500.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$24.42M	-$24.42M
YoY Change
Total Liabilities & Shareholders Equity	$16.58M	$16.58M
YoY Change	-36.06%	-36.06%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2895130	shares
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001100397
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent		usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts		usd
CY2022Q4	ADXS	Intangible Assets Net Foreign Excluding Goodwill IntangibleAssetsNetForeignExcludingGoodwill		usd
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	ADXS	Proceed From Asset Deal Current ProceedFromAssetDealCurrent		usd
CY2022Q4	ADXS	Long Term Warrant Liability LongTermWarrantLiability		usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent		usd
CY2023	us-gaap	Gross Profit GrossProfit		usd
CY2023	ADXS	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants		usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2022	ADXS	Remeasurement Of Long Term Warrant Liability RemeasurementOfLongTermWarrantLiability		usd
CY2022	ADXS	Remeasurement Of Side Letter Agreements RemeasurementOfSideLetterAgreements		usd
CY2022	ADXS	Remeasurement Of Convertible Note RemeasurementOfConvertibleNote		usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities		usd
CY2022	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets		usd
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	ADXS	Lease Liabilities Arising From New Rightofuse Assets LeaseLiabilitiesArisingFromNewRightofuseAssets		usd
CY2023	ADXS	Noncash Deferred Issuance Costs Not Yet Paid NoncashDeferredIssuanceCostsNotYetPaid		usd
CY2023Q4	ADXS	Restricted Cash In Other Assets RestrictedCashInOtherAssets		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate		pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits		pure
CY2022Q4	ADXS	Deferred Tax Assets Tax Deferred Warrantand Other Fair Value Liabilities DeferredTaxAssetsTaxDeferredWarrantandOtherFairValueLiabilities		usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	ADXS	Remeasurement Of Long Term Warrant Liability RemeasurementOfLongTermWarrantLiability		usd
CY2022	ADXS	Remeasurement Of Side Letter Agreements RemeasurementOfSideLetterAgreements		usd
CY2022	ADXS	Remeasurement Of Convertible Note RemeasurementOfConvertibleNote		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36138
CY2023	dei	Entity Registrant Name EntityRegistrantName	AYALA PHARMACEUTICALS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	02-0563870
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	9 Deer Park Drive
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite K-1
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Monmouth Junction
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08852
CY2023	dei	City Area Code CityAreaCode	(609)
CY2023	dei	Local Phone Number LocalPhoneNumber	452-9813
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	3700000	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42633400	shares
CY2023	dei	Auditor Firm AuditorFirmId	1281
CY2023	dei	Auditor Name AuditorName	KOST FORER GABBAY & KASIERER
CY2023	dei	Auditor Location AuditorLocation	Tel-Aviv, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4882000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2408000	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	234000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2646000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	546000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	7528000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	3188000	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	1953000	usd
CY2023Q4	ADXS	Intangible Assets Net Foreign Excluding Goodwill IntangibleAssetsNetForeignExcludingGoodwill	3898000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	4500000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	102000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1462000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	540000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	960000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	11000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	206000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	9051000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	4581000	usd
CY2023Q4	us-gaap	Assets Assets	16579000	usd
CY2022Q4	us-gaap	Assets Assets	7769000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	6076000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4080000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	166000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	419000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5554000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	708000	usd
CY2023Q4	ADXS	Side Agreement And Reinvestment Rights SideAgreementAndReinvestmentRights	8436000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	786000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	994000	usd
CY2023Q4	ADXS	Proceed From Asset Deal Current ProceedFromAssetDealCurrent	4000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25018000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6201000	usd
CY2023Q4	ADXS	Long Term Warrant Liability LongTermWarrantLiability	6057000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	8141000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1771000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1335000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1332000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15978000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2667000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	37480000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11896845	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2695067	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11857393	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2638663	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	12000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	172797000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	148052000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-197226000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-149154000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-24417000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1099000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16579000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7769000	usd
CY2023	us-gaap	Revenues Revenues	13000	usd
CY2022	us-gaap	Revenues Revenues	692000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	602000	usd
CY2022	us-gaap	Gross Profit GrossProfit	90000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24081000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27851000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12185000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9742000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-36266000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-37503000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15718000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	74000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-51984000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37429000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3912000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	584000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-48072000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38013000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.99
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.99
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-13.13
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-13.13
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6019063	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6019063	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2895130	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	34158000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	14000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	512000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2244000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38013000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1099000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1099000	usd
CY2023	ADXS	Stock Issued During Period Shares Exercise Of Warrants StockIssuedDuringPeriodSharesExerciseOfWarrants	246192000	shares
CY2023	us-gaap	Payments For Merger Related Costs PaymentsForMergerRelatedCosts	3153000	usd
CY2023	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	1815951000	shares
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	16949000	usd
CY2023	ADXS	Stock Issued During Period Shares Acquisition StockIssuedDuringPeriodSharesAcquisition	5913480000	shares
CY2023	ADXS	Stock Issued During Period Value Acquisition StockIssuedDuringPeriodValueAcquisition	5514000	usd
CY2023	ADXS	Stock Issued During Period Shares Conversion Of Safe StockIssuedDuringPeriodSharesConversionOfSafe	1145053000	shares
CY2023	ADXS	Stock Issued During Period Value Conversion Of Safe StockIssuedDuringPeriodValueConversionOfSafe	1068000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1223000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-48072000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-24417000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-24417000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-48072000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38013000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1223000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2244000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	369000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	162000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	145000	usd
CY2023	ADXS	Remeasurement Of Long Term Warrant Liability RemeasurementOfLongTermWarrantLiability	-5854000	usd
CY2023	ADXS	Remeasurement Of Side Letter Agreements RemeasurementOfSideLetterAgreements	-7751000	usd
CY2023	ADXS	Remeasurement Of Convertible Note RemeasurementOfConvertibleNote	-2141000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1491000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-2232000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-234000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	234000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-724000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-472000	usd
CY2023	ADXS	Increase Decrease In Operating Lease Rightofuse Assets IncreaseDecreaseInOperatingLeaseRightofuseAssets	-1429000	usd
CY2022	ADXS	Increase Decrease In Operating Lease Rightofuse Assets IncreaseDecreaseInOperatingLeaseRightofuseAssets	-288000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1641000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-536000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3123000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	121000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-248000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-767000	usd
CY2023	ADXS	Increase Decrease In Uncertain Tax Position IncreaseDecreaseInUncertainTaxPosition	448000	usd
CY2022	ADXS	Increase Decrease In Uncertain Tax Position IncreaseDecreaseInUncertainTaxPosition	465000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-26000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29485000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34510000	usd
CY2023	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	4000000	usd
CY2023	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1909000	usd
CY2023	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-37000	usd
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	2000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5946000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6000000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	14000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	512000	usd
CY2023	ADXS	Issuance Of Shares Upon Merger Net Of Issuance Costs IssuanceOfSharesUponMergerNetOfIssuanceCosts	20001000	usd
CY2022	ADXS	Issuance Of Shares Upon Merger Net Of Issuance Costs IssuanceOfSharesUponMergerNetOfIssuanceCosts	-615000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26001000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-103000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2488000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34615000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2724000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37339000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5212000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2724000	usd
CY2022	ADXS	Lease Liabilities Arising From New Rightofuse Assets LeaseLiabilitiesArisingFromNewRightofuseAssets	537000	usd
CY2022	ADXS	Noncash Deferred Issuance Costs Not Yet Paid NoncashDeferredIssuanceCostsNotYetPaid	1338000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	371000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	244000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4882000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2408000	usd
CY2023Q4	ADXS	Restricted Cash In Prepaid Expenses And Other Current Assets RestrictedCashInPrepaidExpensesAndOtherCurrentAssets	330000	usd
CY2022Q4	ADXS	Restricted Cash In Prepaid Expenses And Other Current Assets RestrictedCashInPrepaidExpensesAndOtherCurrentAssets	110000	usd
CY2022Q4	ADXS	Restricted Cash In Other Assets RestrictedCashInOtherAssets	206000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5212000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2724000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29500000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-48100000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4900000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25000000.0	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-197200000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zuHK5KtQ1sa1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zQxy9UG8sHpg">Use of Estimates</span>:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1	pure
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	200000	usd
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	300000	usd
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1	pure
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06	pure
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06	pure
CY2023Q4	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P12M
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zWvHKf8r9vt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_ztkFhKYcPcRk">Concentrations of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. Bank deposits are held by accredited financial institutions and these deposits may at times be in excess of insured limits. Money Market funds are of Prime A and only invested in government issued securities. The Company limits its credit risk associated with cash and cash equivalents by placing them with financial institutions that it believes are of high-quality credit rating. The Company has not experienced any losses on its deposits of cash or cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company did not have any customers as of December 31, 2023. The Company’s trade receivables as of December 31, 2022 were from one customer. In addition, the potential risk of loss with any one counterparty resulting from this type of credit risk is monitored on an ongoing basis. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3898000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3898000	usd
CY2023Q4	ADXS	Rights Of Use Of Assets And Property And Equipment RightsOfUseOfAssetsAndPropertyAndEquipment	642000	usd
CY2022Q4	ADXS	Rights Of Use Of Assets And Property And Equipment RightsOfUseOfAssetsAndPropertyAndEquipment	2422000	usd
CY2023Q4	ADXS	Rights Of Use Of Assets And Property And Equipment RightsOfUseOfAssetsAndPropertyAndEquipment	642000	usd
CY2022Q4	ADXS	Rights Of Use Of Assets And Property And Equipment RightsOfUseOfAssetsAndPropertyAndEquipment	2422000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	0.1874	shares
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets	130000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	4500000	usd
CY2023	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	1000000.0	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1751000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1352000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1620000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	812000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	660000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	540000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	960000	usd
CY2023	us-gaap	Depreciation Depreciation	334000	usd
CY2022	us-gaap	Depreciation Depreciation	162000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	145000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1750000	usd
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2287000	usd
CY2019Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P63M
CY2019Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P60M
CY2019Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	500000	usd
CY2021Q1	us-gaap	Payments For Rent PaymentsForRent	29000	usd
	ADXS	Lessee Finance Leases Renewal Term LesseeFinanceLeasesRenewalTerm	2023-03-31
CY2023Q1	ADXS	Lessee Finance Leases Renewal Term LesseeFinanceLeasesRenewalTerm	2025-03-31
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	36000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	65000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	65000	usd
CY2023	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	238000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	102000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	175000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1462000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1751000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	166000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	419000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1332000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	175000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	457000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	442000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	19000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	10000	usd
CY2023	us-gaap	Lease Cost LeaseCost	476000	usd
CY2022	us-gaap	Lease Cost LeaseCost	452000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1416	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	171000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	180000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	175000	usd
CY2023	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	4500000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	4500000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3800000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0098	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0353	pure
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	33000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	33000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	32000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3800000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3898000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	32000	usd
CY2023	ADXS	Milestone Payments MilestonePayments	600000	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	200000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	22965771	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	22965771	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	337320	shares
CY2022Q4	ADXS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding And Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice	25.08
CY2022	ADXS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm	P1Y1M20D
CY2022Q4	ADXS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding And Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableAggregateIntrinsicValue	144083000	usd
CY2023	ADXS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Merged Warrants ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsMergedWarrants	377818	shares
CY2023	ADXS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Merged Warrants Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsMergedWarrantsWeightedAverageExercisePrice	53.45
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	22500500	shares
CY2023	ADXS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice	0.34
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	249867	shares
CY2023	ADXS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice	0.05
CY2023Q4	ADXS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Warrants ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWarrants	22965771	shares
CY2023Q4	ADXS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	1.58
CY2023	ADXS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm	P4Y10M2D
CY2023Q4	ADXS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue	7537668000	usd
CY2023Q4	ADXS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Warrants ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWarrants	22790706	shares
CY2023Q4	ADXS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	1.15
CY2023	ADXS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm	P4Y10M2D
CY2023Q4	ADXS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableAggregateIntrinsicValue	7537668000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4.0	usd
CY2023Q4	us-gaap	Share Price SharePrice	0.67
CY2023Q4	us-gaap	Share Price SharePrice	0.77
CY2023Q3	us-gaap	Share Price SharePrice	1.15
CY2023	ADXS	Gain On Fair Value Of Warrant Liability GainOnFairValueOfWarrantLiability	6000000.0	usd
CY2023	ADXS	Loss On Fair Value Of Liability LossOnFairValueOfLiability	7200000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	22634	usd
CY2023	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	39452	shares
CY2022	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	80839	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.80	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4M2D
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1223000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2244000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	197897	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.34
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M6D
CY2023	ADXS	Share Based Compensation Arrangement By Share Based Payment Award Options Merger In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMergerInPeriodGross	9815	shares
CY2023	ADXS	Share Based Compensation Arrangements By Share Based Payment Award Options Merger In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsMergerInPeriodWeightedAverageExercisePrice	1243.88
CY2023	ADXS	Sharebased Compensation Arrangement By Sharebased Payment Award Options Merger Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsMergerWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	6539	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	38.34
CY2023	ADXS	Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeited Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	98281	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	38.91
CY2023	ADXS	Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm2	P5Y11M1D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	102892	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	151.86
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	90596	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	131.77
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y7D
CY2023	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	(i) a permanent reduction to the statutory federal corporate income tax rate from 35% (top rate) to 21% (flat rate) effective for tax years beginning after December 31, 2017 (ii) a new tax deduction in the amount of 37.5% of “foreign derived intangible income” that effectively reduces the federal corporate tax on certain qualified foreign derived sales/licenses/leases and service income in excess of a base amount to 13.125% (as compared to the regular corporate income tax rate of 21%); (iii) stricter limitation on the tax deductibility of business interest expense; (iv) a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain rules designed to prevent erosion of the U.S. income tax base) (v) a one-time deemed repatriation tax on accumulated offshore earnings held in cash and illiquid assets, with the latter taxed at a lower rate and (vi) an expansion of the U.S. controlled foreign corporation (“CFC”) anti deferral starting with the CFC’s first tax year beginning in 2018 intended to tax in the U.S. “global intangible low-taxed income” (“GILTI”)
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-49912000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-36674000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2072000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-755000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-51984000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37429000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-3912000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	584000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3912000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	584000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.3796	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0072	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	-0.0003	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0.0006	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0049	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0126	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Gilti Percent EffectiveIncomeTaxRateReconciliationGiltiPercent	0.0000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Gilti Percent EffectiveIncomeTaxRateReconciliationGiltiPercent	0.0000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0005	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0001	pure
CY2023	ADXS	Effective Income Tax Rate Reconciliation Uncertain Tax Positions Percent EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent	-0.0081	pure
CY2022	ADXS	Effective Income Tax Rate Reconciliation Uncertain Tax Positions Percent EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent	-0.0115	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.4844	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2551	pure
CY2023	ADXS	Effective Income Tax Rate Reconciliation Federal Tax Reform Rate Change Percent EffectiveIncomeTaxRateReconciliationFederalTaxReformRateChangePercent	0.0000	pure
CY2022	ADXS	Effective Income Tax Rate Reconciliation Federal Tax Reform Rate Change Percent EffectiveIncomeTaxRateReconciliationFederalTaxReformRateChangePercent	0.0000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0414	pure
CY2023	ADXS	Effective Income Tax Rate Reconciliation Provision To Return Percent EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent	0.0168	pure
CY2022	ADXS	Effective Income Tax Rate Reconciliation Provision To Return Percent EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent	0.0167	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0001	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0110	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0751	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0156	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	69040000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	27592000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	16668000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4862000	usd
CY2023Q4	ADXS	Deferred Tax Assets Intangible And Other Related Assets DeferredTaxAssetsIntangibleAndOtherRelatedAssets	3095000	usd
CY2022Q4	ADXS	Deferred Tax Assets Intangible And Other Related Assets DeferredTaxAssetsIntangibleAndOtherRelatedAssets	2990000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	36632000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3074000	usd
CY2023Q4	ADXS	Deferred Tax Assets Accrued Expenses DeferredTaxAssetsAccruedExpenses	169000	usd
CY2022Q4	ADXS	Deferred Tax Assets Accrued Expenses DeferredTaxAssetsAccruedExpenses	72000	usd
CY2023Q4	ADXS	Deferred Tax Assets Tax Deferred Warrantand Other Fair Value Liabilities DeferredTaxAssetsTaxDeferredWarrantandOtherFairValueLiabilities	5142000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	4782000	usd
CY2023Q4	ADXS	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	460000	usd
CY2022Q4	ADXS	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	410000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	135988000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	39000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	135570000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	38652000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	418000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	348000	usd
CY2023Q4	ADXS	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	-418000	usd
CY2022Q4	ADXS	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	-348000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	418000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	348000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	135600000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	214900000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	1800000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	1300000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1335000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	858000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Foreign Currency Translation UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation	13000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Foreign Currency Translation UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation	36000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	423000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	441000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1771000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1335000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-48072000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-48072000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-38013000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-38013000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6019063	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6019063	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2895130	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2895130	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	22965771	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	87453	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	102892	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	197897	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23068663	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	285350	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.99
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.99
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-13.13
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-13.13
CY2023	ADXS	Prepaid Expenses And Other Current Assets PrepaidExpensesAndOtherCurrentAssets	<p id="xdx_807_ecustom--PrepaidExpensesAndOtherCurrentAssets_z9RkZPQCDVXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>15. <span id="xdx_824_zu3VMXFbgCPh">Prepaid Expenses and Other Current Assets</span></b></p> <p id="xdx_891_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zM8gg9rZU54j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> <span id="xdx_8BD_zAK7DNEpJIL" style="display: none">Schedule of Prepaid Expenses and Other Current Assets</span></b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20231231_zXI1xBvv68zh" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20221231_z69RJgBUK2Z2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--PrepaidInsurance_iI_pn3n3_maPECzcAg_z2pZdPhjQjel" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; font-size: 10pt; text-align: left">Prepaid Insurances</td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 15%; font-size: 10pt; text-align: right">2,144</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 15%; font-size: 10pt; text-align: right">431</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DepositsAssetsCurrent_iI_pn3n3_maPECzcAg_zhZmjmGUyZ18" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Short-term restricted bank deposits</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">330</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">110</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPECzcAg_znXcKNogSw2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Other Assets</td><td style="font-size: 10pt; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">172</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">5</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PrepaidExpenseCurrent_iTI_pn3n3_mtPECzcAg_zF10KHagTwTe" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,646</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">546</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zmXbV3Xt82Zh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p>
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2144000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	431000	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	330000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	110000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	172000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2646000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	546000	usd
CY2023	ADXS	Remeasurement Of Long Term Warrant Liability RemeasurementOfLongTermWarrantLiability	-5854000	usd
CY2023	ADXS	Remeasurement Of Side Letter Agreements RemeasurementOfSideLetterAgreements	-7751000	usd
CY2023	ADXS	Remeasurement Of Convertible Note RemeasurementOfConvertibleNote	-2141000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	28000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	74000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15718000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	74000	usd

Files In Submission

Name	View Source	Status
0001493152-24-014822-index-headers.html	Edgar Link	pending
0001493152-24-014822-index.html	Edgar Link	pending
0001493152-24-014822.txt	Edgar Link	pending
0001493152-24-014822-xbrl.zip	Edgar Link	pending
adxs-20231231.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
adxs-20231231_def.xml	Edgar Link	unprocessable
adxs-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
adxs-20231231_cal.xml	Edgar Link	unprocessable
adxs-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Ayala Pharmaceuticals, Inc.

2024 Q2 Form 10-K Financial Statement

#000149315224014822 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission